Lasse Bjerg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lasse Bjerg has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Rinse Witte
Department of Public Health, Aarhus University, Aarhus, Denmark
12 shared publications - Adam Hulman
Department of Public Health, Aarhus University, Aarhus, Denmark
8 shared publications - Jonas Rosborg Schaarup
Department of Public Health Aarhus University Aarhus Denmark
8 shared publications Morten Charles
Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark
8 shared publications- Signe Toft Andersen
Steno Diabetes Center Aarhus, Palle Juul-Jensens Boulevard 11, Aarhus, Central Denmark Region, 8200, Denmark, +45 23 70 74 81
7 shared publications - Anders Aasted Isaksen
Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark
6 shared publications
Latest Publications
- Open Access
- 6 March 2026
- Published by BMJ in BMJ Open Diabetes Research & Care
- Vol. 14 (2) , e004995
Cardiovascular autonomic dysfunction is linked with arterial stiffness across glucose metabolism: the Maastricht study
Objective: To ascertain the cross-sectional association between cardiovascular autonomic dysfunction and arterial stiffness across glucose metabolism status. Research design and methods: We performed a cross-sectional analysis of participants of the Maastricht study. Cardiovascular autonomic function was based on heart rate variability (HRV) indices from 24-hour ECG recordings and summarized in z-scores for time and frequency domains. Aortic and carotid stiffness were assessed by carotid-femoral pulse wave velocity (PWV) and carotid artery distensibility (CD), respectively. We used multiple linear regression to study the associations and adjusted for demographic and lifestyle factors and a range of cardiovascular risk factors. We tested for effect modification of the associations by glucose metabolism status. Results: PWV and CD measures were available in 3673 and 1802 participants, respectively (median (25th; 75th percentile) age: 60 years (53; 66), 51% women, 20% type 2 diabetes by design. Participants with lower HRV had higher aortic stiffness. Per SD lower time-domain and frequency-domain HRV z-scores were associated with 2.8% (95% CI 2.1% to 3.4%) and 2.8% (95% CI 2.1% to 3.5%) higher PWV, respectively. Similar trends were observed for carotid stiffness, with 3.2% (95% CI 1.4% to 5.0%) and 3.1% (95% CI 1.2% to 5.0%) lower CD per SD lower time-domain and frequency-domain HRV, respectively. The magnitude of these associations was higher in groups with prediabetes and type 2 diabetes compared with those with normal glucose metabolism, with evidence of effect modification by glucose metabolism status (p value for interaction: <0.01 for prediabetes and <0.05 to <0.10 for type 2 diabetes, both compared with normal glucose metabolism). Conclusion: Cardiovascular autonomic dysfunction is associated with higher aortic and carotid stiffness, especially in people with dysglycemia.
- 6 March 2026
- Published by BMJ in BMJ Open Diabetes Research & Care
- Vol. 14 (2) , e004995
Open AccessCardiovascular autonomic dysfunction is linked with arterial stiffness across glucose metabolism: the Maastricht study
Objective: To ascertain the cross-sectional association between cardiovascular autonomic dysfunction and arterial stiffness across glucose metabolism status. Research design and methods: We performed a cross-sectional analysis of participants of the Maastricht study. Cardiovascular autonomic function was based on heart rate variability (HRV) indices from 24-hour ECG recordings and summarized in z-scores for time and frequency domains. Aortic and carotid stiffness were assessed by carotid-femoral pulse wave velocity (PWV) and carotid artery distensibility (CD), respectively. We used multiple linear regression to study the associations and adjusted for demographic and lifestyle factors and a range of cardiovascular risk factors. We tested for effect modification of the associations by glucose metabolism status. Results: PWV and CD measures were available in 3673 and 1802 participants, respectively (median (25th; 75th percentile) age: 60 years (53; 66), 51% women, 20% type 2 diabetes by design. Participants with lower HRV had higher aortic stiffness. Per SD lower time-domain and frequency-domain HRV z-scores were associated with 2.8% (95% CI 2.1% to 3.4%) and 2.8% (95% CI 2.1% to 3.5%) higher PWV, respectively. Similar trends were observed for carotid stiffness, with 3.2% (95% CI 1.4% to 5.0%) and 3.1% (95% CI 1.2% to 5.0%) lower CD per SD lower time-domain and frequency-domain HRV, respectively. The magnitude of these associations was higher in groups with prediabetes and type 2 diabetes compared with those with normal glucose metabolism, with evidence of effect modification by glucose metabolism status (p value for interaction: <0.01 for prediabetes and <0.05 to <0.10 for type 2 diabetes, both compared with normal glucose metabolism). Conclusion: Cardiovascular autonomic dysfunction is associated with higher aortic and carotid stiffness, especially in people with dysglycemia.
- Open Access
- 15 December 2025
- Published by BMJ in BMJ Digital Health & AI
- Vol. 1 (1) , e000090
Trust in large language model-based solutions in healthcare among people with and without diabetes: a cross-sectional survey from the Health in Central Denmark cohort
Objective: Large language models have gained significant public awareness since ChatGPT’s release in 2022. This study describes the perception of chatbots in healthcare among people with and without diabetes. Methods and analysis: In 2024, an online survey was sent to 136 229 people, aged 18–89 years in the Health in Central Denmark cohort, including equestions related to the perception of artificial intelligence (AI) and chatbots. Questions assessed trust in chatbots in various healthcare scenarios (lifestyle, diagnostic, contact with general practitioner (GP) and emergency contact) alongside participants’ level of experience with ChatGPT. In one item, participants were randomly presented with either a more severe (emergency) or less severe (GP contact) scenario. We used multinomial logistic regression to investigate the association of diabetes status and demographic characteristics with trust in chatbots in different scenarios. Results: 39 109 participants completed the questionnaire. The majority were aware of AI (94%), although fewer had heard of ChatGPT (76%), and only 21% had tried it. Most participants trusted chatbots with involvement of healthcare professionals (HCPs) (49%–55%), while few trusted without them (3%–6%). The degree of trust depended on the severity of the scenario, demonstrated by lower odds (OR 0.63, 95% CI 0.60 to 0.66) of trusting the chatbot under the control of HCPs in emergency care compared with contact with the GP. Type 2 diabetes, but not type 1 diabetes, was associated with less trust in chatbots than people without diabetes. Moreover, age, sex, duration of education and experience with ChatGPT also had an impact on trust. Conclusion: Chatbots are seen as supportive tools among public users when controlled by HCPs but are met with more scepticism in more severe situations. Digital exclusion risks and demographic differences, such as age, sex and disease-specific conditions (eg, type 2 diabetes), need to be addressed to ensure equitable and meaningful implementation.
- 15 December 2025
- Published by BMJ in BMJ Digital Health & AI
- Vol. 1 (1) , e000090
Open AccessTrust in large language model-based solutions in healthcare among people with and without diabetes: a cross-sectional survey from the Health in Central Denmark cohort
Objective: Large language models have gained significant public awareness since ChatGPT’s release in 2022. This study describes the perception of chatbots in healthcare among people with and without diabetes. Methods and analysis: In 2024, an online survey was sent to 136 229 people, aged 18–89 years in the Health in Central Denmark cohort, including equestions related to the perception of artificial intelligence (AI) and chatbots. Questions assessed trust in chatbots in various healthcare scenarios (lifestyle, diagnostic, contact with general practitioner (GP) and emergency contact) alongside participants’ level of experience with ChatGPT. In one item, participants were randomly presented with either a more severe (emergency) or less severe (GP contact) scenario. We used multinomial logistic regression to investigate the association of diabetes status and demographic characteristics with trust in chatbots in different scenarios. Results: 39 109 participants completed the questionnaire. The majority were aware of AI (94%), although fewer had heard of ChatGPT (76%), and only 21% had tried it. Most participants trusted chatbots with involvement of healthcare professionals (HCPs) (49%–55%), while few trusted without them (3%–6%). The degree of trust depended on the severity of the scenario, demonstrated by lower odds (OR 0.63, 95% CI 0.60 to 0.66) of trusting the chatbot under the control of HCPs in emergency care compared with contact with the GP. Type 2 diabetes, but not type 1 diabetes, was associated with less trust in chatbots than people without diabetes. Moreover, age, sex, duration of education and experience with ChatGPT also had an impact on trust. Conclusion: Chatbots are seen as supportive tools among public users when controlled by HCPs but are met with more scepticism in more severe situations. Digital exclusion risks and demographic differences, such as age, sex and disease-specific conditions (eg, type 2 diabetes), need to be addressed to ensure equitable and meaningful implementation.
- Open Access
- 25 November 2025
- Published by Springer Nature in npj Digital Medicine
- Vol. 8 (1)
Changes in public perception of artificial intelligence in healthcare after exposure to ChatGPT
The public perception of artificial intelligence (AI) in healthcare is key to its large-scale acceptance and implementation. This study investigated how exposure to ChatGPT changed public perception of AI in healthcare, using baseline and follow-up data from 5899 survey participants reporting their perception of AI in 2022 (before ChatGPT’s launch) and 2024, and ChatGPT use in 2024. Multinomial multivariate logistic regression was used to model how exposure to ChatGPT use affected changes in perception of AI. At follow-up, 1195 individuals (20%) had been exposed to ChatGPT use, which was associated with higher odds of changing perception of AI to beneficial (OR 3.21 [95% CI: 2.34–4.40]) among individuals who were unsure at baseline, and lower odds of changing to uncertainty from more defined baseline perceptions. This study demonstrates the potential for reducing uncertainty and improving public perception of AI in healthcare through exposure to AI tools.
- 25 November 2025
- Published by Springer Nature in npj Digital Medicine
- Vol. 8 (1)
Open AccessChanges in public perception of artificial intelligence in healthcare after exposure to ChatGPT
The public perception of artificial intelligence (AI) in healthcare is key to its large-scale acceptance and implementation. This study investigated how exposure to ChatGPT changed public perception of AI in healthcare, using baseline and follow-up data from 5899 survey participants reporting their perception of AI in 2022 (before ChatGPT’s launch) and 2024, and ChatGPT use in 2024. Multinomial multivariate logistic regression was used to model how exposure to ChatGPT use affected changes in perception of AI. At follow-up, 1195 individuals (20%) had been exposed to ChatGPT use, which was associated with higher odds of changing perception of AI to beneficial (OR 3.21 [95% CI: 2.34–4.40]) among individuals who were unsure at baseline, and lower odds of changing to uncertainty from more defined baseline perceptions. This study demonstrates the potential for reducing uncertainty and improving public perception of AI in healthcare through exposure to AI tools.
- Open Access
- 9 July 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 27 (9) , 5147-5159
Cardiovascular autonomic dysfunction precedes cardiovascular disease and all‐cause mortality: 11‐year follow‐up in the ADDITION ‐ PRO study
Aim: We aim to determine the impact of multiday heart rate variability (HRV) on the risk of major adverse cardiovascular events (MACE), heart failure and mortality in people at high risk of diabetes. Materials and Methods: Multiday HRV and mean heart rate (mHR) were measured in 1627 participants from the ADDITION‐PRO study between 2009 and 2011. As measurement for HRV, we calculated a proxy for standard deviation of normal heartbeat (SDNN) both weekly, daily and hourly. Data on MACE and all‐cause mortality were obtained from Danish patient registers until 2021. We fitted Poisson regression to determine incidence rate ratios (IRR) for MACE (myocardial infarction, stroke and cardiovascular death), heart failure and all‐cause mortality. Results: Mean (SD) age was 66 years (7), and 47% were women. The population had a mean (SD) multiday SDNN of 139.0 (32.3) milliseconds. Multiday HRV index SDNN showed an IRR of 0.82 (CI: 0.69; 0.97), 0.76 (CI: 0.58; 0.99) and 0.79 (CI: 0.66; 0.94) per SD for MACE, heart failure and all‐cause mortality, respectively. SDNN measurements taken from 6:00 AM to 7:00 AM showed the strongest association with the risk of MACE. Lower SDNN was associated with all‐cause mortality across all hours of the day. Adjustment for physical acceleration and heart rate did not materially change the magnitude of these associations. Conclusion: Cardiovascular autonomic dysfunction, measured by multiday HRV, is linked with MACE, heart failure and all‐cause mortality. Certain time frames of the day for HRV and heart rate under free‐living conditions showed a higher risk of cardiovascular disease.
- 9 July 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 27 (9) , 5147-5159
Open AccessCardiovascular autonomic dysfunction precedes cardiovascular disease and all‐cause mortality: 11‐year follow‐up in the ADDITION ‐ PRO study
Aim: We aim to determine the impact of multiday heart rate variability (HRV) on the risk of major adverse cardiovascular events (MACE), heart failure and mortality in people at high risk of diabetes. Materials and Methods: Multiday HRV and mean heart rate (mHR) were measured in 1627 participants from the ADDITION‐PRO study between 2009 and 2011. As measurement for HRV, we calculated a proxy for standard deviation of normal heartbeat (SDNN) both weekly, daily and hourly. Data on MACE and all‐cause mortality were obtained from Danish patient registers until 2021. We fitted Poisson regression to determine incidence rate ratios (IRR) for MACE (myocardial infarction, stroke and cardiovascular death), heart failure and all‐cause mortality. Results: Mean (SD) age was 66 years (7), and 47% were women. The population had a mean (SD) multiday SDNN of 139.0 (32.3) milliseconds. Multiday HRV index SDNN showed an IRR of 0.82 (CI: 0.69; 0.97), 0.76 (CI: 0.58; 0.99) and 0.79 (CI: 0.66; 0.94) per SD for MACE, heart failure and all‐cause mortality, respectively. SDNN measurements taken from 6:00 AM to 7:00 AM showed the strongest association with the risk of MACE. Lower SDNN was associated with all‐cause mortality across all hours of the day. Adjustment for physical acceleration and heart rate did not materially change the magnitude of these associations. Conclusion: Cardiovascular autonomic dysfunction, measured by multiday HRV, is linked with MACE, heart failure and all‐cause mortality. Certain time frames of the day for HRV and heart rate under free‐living conditions showed a higher risk of cardiovascular disease.
- Open Access
Trust in large language model-based solutions in healthcare among people with and without diabetes: a cross-sectional survey from the Health in Central Denmark cohort
Background: Large language models have gained significant public awareness since ChatGPT’s release in 2022. This study describes the perception of chatbot-assisted healthcare among people with and without diabetes. Methods: In 2024, an online survey was sent to 136,229 people, aged 18–89 years in the Health in Central Denmark cohort, including eight questions related to the perception of AI and chatbots. Questions assessed trust in chatbots in various healthcare scenarios (lifestyle, diagnostic, contact with general practitioner (GP), and emergency contact) alongside participants’ level of experience with ChatGPT. In one item, participants were randomly presented with either a more severe (emergency) or less severe (GP contact) scenario. We used multinomial logistic regression to investigate the association of diabetes status and demographic characteristics with trust in chatbots in different scenarios. Findings: 39,109 participants completed the questionnaire. The majority were aware of AI (94%), though fewer had heard of ChatGPT (76%), and only 21% had tried it. Most participants trusted chatbots with involvement of healthcare professionals (HCP) (49-55%), while few trusted without them (3–6%). The degree of trust depended on the severity of the scenario, demonstrated by lower odds (OR: 0.63 [95% CI: 0.60: 0.66]) of trusting the chatbot under the control of HCP in emergency care compared to contact with the general practitioner. Type 2 diabetes but not type 1 diabetes was associated with less trust in chatbots than people without diabetes. Moreover, age, sex, education, and experience with ChatGPT also had an impact on trust. Interpretation: Chatbots are seen as supportive tools among public users when controlled by HCPs but are met with more skepticism in more severe situations. Digital exclusion risks and demographic differences, such as age, sex, and disease-specific conditions (e.g., type 2 diabetes) needs, must be addressed to ensure equitable and meaningful implementation. Research in Context: Evidence before this study: Earlier studies have highlighted the generally positive attitudes of patients and the public towards the applications of artificial intelligence (AI) in healthcare. However, it noted a lack of clear characteristics associated with the acceptance of AI, with many patients preferring AI solutions to remain under human supervision rather than fully replacing healthcare professionals (HCPs). Since ChatGPT emerged in 2022, AI tools have been widely available to the general public, and many healthcare-specific chatbots are now being evaluated in random control trails. Some patients are already turning to tools like ChatGPT for medical advice, further underscoring the need to understand user perceptions, particularly in relation to diabetes and other characteristics, as these technologies may become integrated into care. Our earlier study showed that among AI applications, chatbots were the most controversial when used in emergency care. Thus, understanding the perception of chatbots in different healthcare contexts is needed, as the level of controversy may depend on their specific role in healthcare. Added value of this study: Our study expands on previous work by engaging a larger cohort of 39,109 participants, which includes a comprehensive representation of older adults and individuals with and without diabetes. Our survey was conducted between February-May 2024, a time when ChatGPT had been accessible for more than 1 year. We assessed trust in chatbot-based healthcare solutions, revealing that, while the majority accepted chatbot assistance under human control, individuals with type 2 diabetes exhibited less trust in such applications compared to those without diabetes or type 1 diabetes. Our findings underscore that the severity and acuteness of healthcare scenarios influenced trust levels. Implications of all available evidence: Our findings suggest that while AI and chatbots are becoming widely available, uncertainty about their benefits and risks in healthcare persists. People view healthcare professionals as playing an important role in supporting them, particularly in severe scenarios, toward adopting chatbot solutions. A patient-centered approach is necessary, with tailored solutions to address variations in trust based on factors such as diabetes status, age, sex, and education. Ensuring the involvement of vulnerable populations, such as the elderly and those with type 2 diabetes, is key to avoiding digital exclusion and making chatbot solutions accessible and meaningful.
Open AccessTrust in large language model-based solutions in healthcare among people with and without diabetes: a cross-sectional survey from the Health in Central Denmark cohort
Background: Large language models have gained significant public awareness since ChatGPT’s release in 2022. This study describes the perception of chatbot-assisted healthcare among people with and without diabetes. Methods: In 2024, an online survey was sent to 136,229 people, aged 18–89 years in the Health in Central Denmark cohort, including eight questions related to the perception of AI and chatbots. Questions assessed trust in chatbots in various healthcare scenarios (lifestyle, diagnostic, contact with general practitioner (GP), and emergency contact) alongside participants’ level of experience with ChatGPT. In one item, participants were randomly presented with either a more severe (emergency) or less severe (GP contact) scenario. We used multinomial logistic regression to investigate the association of diabetes status and demographic characteristics with trust in chatbots in different scenarios. Findings: 39,109 participants completed the questionnaire. The majority were aware of AI (94%), though fewer had heard of ChatGPT (76%), and only 21% had tried it. Most participants trusted chatbots with involvement of healthcare professionals (HCP) (49-55%), while few trusted without them (3–6%). The degree of trust depended on the severity of the scenario, demonstrated by lower odds (OR: 0.63 [95% CI: 0.60: 0.66]) of trusting the chatbot under the control of HCP in emergency care compared to contact with the general practitioner. Type 2 diabetes but not type 1 diabetes was associated with less trust in chatbots than people without diabetes. Moreover, age, sex, education, and experience with ChatGPT also had an impact on trust. Interpretation: Chatbots are seen as supportive tools among public users when controlled by HCPs but are met with more skepticism in more severe situations. Digital exclusion risks and demographic differences, such as age, sex, and disease-specific conditions (e.g., type 2 diabetes) needs, must be addressed to ensure equitable and meaningful implementation. Research in Context: Evidence before this study: Earlier studies have highlighted the generally positive attitudes of patients and the public towards the applications of artificial intelligence (AI) in healthcare. However, it noted a lack of clear characteristics associated with the acceptance of AI, with many patients preferring AI solutions to remain under human supervision rather than fully replacing healthcare professionals (HCPs). Since ChatGPT emerged in 2022, AI tools have been widely available to the general public, and many healthcare-specific chatbots are now being evaluated in random control trails. Some patients are already turning to tools like ChatGPT for medical advice, further underscoring the need to understand user perceptions, particularly in relation to diabetes and other characteristics, as these technologies may become integrated into care. Our earlier study showed that among AI applications, chatbots were the most controversial when used in emergency care. Thus, understanding the perception of chatbots in different healthcare contexts is needed, as the level of controversy may depend on their specific role in healthcare. Added value of this study: Our study expands on previous work by engaging a larger cohort of 39,109 participants, which includes a comprehensive representation of older adults and individuals with and without diabetes. Our survey was conducted between February-May 2024, a time when ChatGPT had been accessible for more than 1 year. We assessed trust in chatbot-based healthcare solutions, revealing that, while the majority accepted chatbot assistance under human control, individuals with type 2 diabetes exhibited less trust in such applications compared to those without diabetes or type 1 diabetes. Our findings underscore that the severity and acuteness of healthcare scenarios influenced trust levels. Implications of all available evidence: Our findings suggest that while AI and chatbots are becoming widely available, uncertainty about their benefits and risks in healthcare persists. People view healthcare professionals as playing an important role in supporting them, particularly in severe scenarios, toward adopting chatbot solutions. A patient-centered approach is necessary, with tailored solutions to address variations in trust based on factors such as diabetes status, age, sex, and education. Ensuring the involvement of vulnerable populations, such as the elderly and those with type 2 diabetes, is key to avoiding digital exclusion and making chatbot solutions accessible and meaningful.
- Open Access
Changes in public perception of AI in healthcare after exposure to ChatGPT
Background Artificial intelligence (AI) is expected to become an integral part of healthcare services, and the widespread adoption of AI tools in all areas of life is making AI accessible to the general public. Public perception of the benefits and risks of AI in healthcare is key to large-scale acceptance and implementation, and is increasingly influenced by first-hand experiences of AI. The aim of this study was to assess how exposure to ChatGPT changed public perception of AI in healthcare. Methods We used baseline and follow-up data from 5,899 survey participants, who reported their perception of AI in 2022 and 2024, and ChatGPT use in 2024. Administrative and healthcare data from nationwide Danish registers was used for weighting and adjustment. Multinomial multivariate logistic regression was used to model how exposure to ChatGPT use affected changes in perception of AI. Results At baseline (before ChatGPT’s launch) 2,236 individuals (37%) were unsure of the benefits and risks of AI in healthcare, 2,384 (40%) perceived net benefits, 1,083 (18%) perceived benefits and risks as equal, and 196 (3.3%) perceived net risks. At follow-up, 1,195 individuals (20%) had been exposed to ChatGPT use, which was associated with higher odds of changing perception of AI to benefits (OR 3.21 [95% CI: 2.34-4.40]) among individuals who were unsure at baseline, and lower odds of changing to uncertainty from more defined baseline perceptions (from benefits (OR 0.32 [0.24-0.42]), equal (OR 0.47 [0.32-0.69]) and risks (OR 0.27 [0.08-0.98])). Conclusion Exposure to ChatGPT was associated with a change towards positive perception of benefits and risks of AI in healthcare among individuals who were uncertain prior to exposure, and individuals with more defined perceptions of AI were less likely to become uncertain after exposure to ChatGPT.
Open AccessChanges in public perception of AI in healthcare after exposure to ChatGPT
Background Artificial intelligence (AI) is expected to become an integral part of healthcare services, and the widespread adoption of AI tools in all areas of life is making AI accessible to the general public. Public perception of the benefits and risks of AI in healthcare is key to large-scale acceptance and implementation, and is increasingly influenced by first-hand experiences of AI. The aim of this study was to assess how exposure to ChatGPT changed public perception of AI in healthcare. Methods We used baseline and follow-up data from 5,899 survey participants, who reported their perception of AI in 2022 and 2024, and ChatGPT use in 2024. Administrative and healthcare data from nationwide Danish registers was used for weighting and adjustment. Multinomial multivariate logistic regression was used to model how exposure to ChatGPT use affected changes in perception of AI. Results At baseline (before ChatGPT’s launch) 2,236 individuals (37%) were unsure of the benefits and risks of AI in healthcare, 2,384 (40%) perceived net benefits, 1,083 (18%) perceived benefits and risks as equal, and 196 (3.3%) perceived net risks. At follow-up, 1,195 individuals (20%) had been exposed to ChatGPT use, which was associated with higher odds of changing perception of AI to benefits (OR 3.21 [95% CI: 2.34-4.40]) among individuals who were unsure at baseline, and lower odds of changing to uncertainty from more defined baseline perceptions (from benefits (OR 0.32 [0.24-0.42]), equal (OR 0.47 [0.32-0.69]) and risks (OR 0.27 [0.08-0.98])). Conclusion Exposure to ChatGPT was associated with a change towards positive perception of benefits and risks of AI in healthcare among individuals who were uncertain prior to exposure, and individuals with more defined perceptions of AI were less likely to become uncertain after exposure to ChatGPT.
- Open Access
Cardiovascular autonomic dysfunction precedes cardiovascular disease and all-cause mortality: 11-year follow-up of the ADDITION-PRO study
Background: Cardiovascular autonomic dysfunction remains a silent complication in people at high risk of diabetes. We aim to determine the impact of week-long heart rate variability (HRV) on the risk of cardiovascular events and mortality in this population. Methods: Week-long HRV and mean heart rate (mHR) were measured in 1,627 participants from the ADDITION-PRO study between 2009-2011. As measurement for HRV, we calculated a proxy for standard deviation of normal heartbeat (SDNN) both weekly, daily and hourly. Data on cardiovascular events (CVD) and all-cause mortality were obtained from Danish patient registers until 2021. We fitted poisson regression to determine incidence rate ratios (IRR) for major adverse cardiovascular events (MACE) (myocardial infarction, stroke, cardiovascular death), heart failure, and all-cause mortality. Results: Mean (SD) age was 66 years (7), and 47 % were women. The population had a mean (SD) week-long SDNN of 139.0 (32.3) ms. Week-long HRV index SDNN showed an IRR of 0.82 (CI: 0.69; 0.97), 0.76 (CI: 0.58; 0.99), and 0.79 (CI: 0.66; 0.94) per SD for MACE, heart failure, and all-cause mortality, respectively. The risk for MACE, heart failure, and all-cause mortality was higher at SDNN values below 120ms. SDNN measurements taken from 6:00-7:00 AM showed the strongest association with the risk of MACE. Lower SDNN was consistently associated with higher all-cause mortality risk across all hours of the day. Adjustment for concurrent physical acceleration and heart rate did not materially change the magnitude of these associations. Night-time heart rate was associated with a higher risk of MACE, heart failure and all-cause mortality. Conclusion: Cardiovascular autonomic dysfunction, measured by week-long HRV, is associated with higher risk of CVD, heart failure and all-cause mortality. Certain time frames of the day for HRV and heart rate under free-living conditions showed higher risk of CVD. Hence, long-term HRV and the diurnal response are linked with CVD risk among people with high risk of diabetes. Studies exploring the benefit of HRV modifications in CVD prevention are warranted.
Open AccessCardiovascular autonomic dysfunction precedes cardiovascular disease and all-cause mortality: 11-year follow-up of the ADDITION-PRO study
Background: Cardiovascular autonomic dysfunction remains a silent complication in people at high risk of diabetes. We aim to determine the impact of week-long heart rate variability (HRV) on the risk of cardiovascular events and mortality in this population. Methods: Week-long HRV and mean heart rate (mHR) were measured in 1,627 participants from the ADDITION-PRO study between 2009-2011. As measurement for HRV, we calculated a proxy for standard deviation of normal heartbeat (SDNN) both weekly, daily and hourly. Data on cardiovascular events (CVD) and all-cause mortality were obtained from Danish patient registers until 2021. We fitted poisson regression to determine incidence rate ratios (IRR) for major adverse cardiovascular events (MACE) (myocardial infarction, stroke, cardiovascular death), heart failure, and all-cause mortality. Results: Mean (SD) age was 66 years (7), and 47 % were women. The population had a mean (SD) week-long SDNN of 139.0 (32.3) ms. Week-long HRV index SDNN showed an IRR of 0.82 (CI: 0.69; 0.97), 0.76 (CI: 0.58; 0.99), and 0.79 (CI: 0.66; 0.94) per SD for MACE, heart failure, and all-cause mortality, respectively. The risk for MACE, heart failure, and all-cause mortality was higher at SDNN values below 120ms. SDNN measurements taken from 6:00-7:00 AM showed the strongest association with the risk of MACE. Lower SDNN was consistently associated with higher all-cause mortality risk across all hours of the day. Adjustment for concurrent physical acceleration and heart rate did not materially change the magnitude of these associations. Night-time heart rate was associated with a higher risk of MACE, heart failure and all-cause mortality. Conclusion: Cardiovascular autonomic dysfunction, measured by week-long HRV, is associated with higher risk of CVD, heart failure and all-cause mortality. Certain time frames of the day for HRV and heart rate under free-living conditions showed higher risk of CVD. Hence, long-term HRV and the diurnal response are linked with CVD risk among people with high risk of diabetes. Studies exploring the benefit of HRV modifications in CVD prevention are warranted.
- Open Access
Cardiovascular autonomic dysfunction is linked with arterial stiffness across glucose metabolism: The Maastricht Study
Objective: To ascertain the cross-sectional association between cardiovascular autonomic function and arterial stiffness across glucose metabolism status. Methods: We performed a cross-sectional analysis of participants of The Maastricht Study without prior CVD. Cardiovascular autonomic function was based on heart rate variability (HRV) indices from 24-hour electrocardiogram recordings and summarized in Z-scores for time and frequency domains. Aortic and carotid stiffness were assessed by carotid-femoral pulse wave velocity (PWV) and carotid artery distensibility (CD), respectively. We used multiple linear regression to study the associations and adjusted for demographic and lifestyle factors and a range of cardiovascular risk factors. We tested the modification of the associations by glucose metabolism status. Results: PWV and CD measures were available in 3671 and 1806 participants, respectively (median (25 th ; 75 th percentile) age: 60 years (53; 66), 51% women, 20 % type 2 diabetes by design. Participants with lower HRV had higher aortic stiffness, as reflected by 2.8% (CI: 2.1; 3.4) and 2.8% (2.1; 3.5) higher PWV per standard deviation (SD) lower composite HRV time-domain and frequency domain Z-score, respectively. Similar trends were observed for carotid stiffness, reflected by 3.2% (1.4; 5.0) and 3.1% (1.2; 5.0) lower CD per SD lower composite HRV time-domain and frequency domain Z-score, respectively. Associations were stronger among people with prediabetes and type 2 diabetes compared to normal glucose metabolism (p-value for interaction for prediabetes: <0.05; and for type 2 diabetes ranging between: <0.05 - <0.10). Conclusion: Cardiovascular autonomic dysfunction is associated with higher aortic and carotid stiffness, especially in people with dysglycemia. Thus, autonomic dysfunction may contribute to cardiovascular risk by affecting vascular stiffness. Short This study investigates the association between cardiovascular autonomic function and arterial stiffness in 3,671 participants of The Maastricht Study without prior CVD. Cardiovascular autonomic function was assessed using 24-hour heart rate variability (HRV). Aortic stiffness was measured by pulse wave velocity (PWV), and carotid stiffness by carotid artery distensibility (CD). Lower HRV was associated with 2.8–3.2% higher PWV and 3.1–3.2% lower CD per SD decrease in HRV Z-scores, with stronger associations observed in individuals with dysglycemia. These findings suggest that autonomic dysfunction may increase cardiovascular risk through effects on vascular stiffness, particularly in prediabetes and diabetes.
Open AccessCardiovascular autonomic dysfunction is linked with arterial stiffness across glucose metabolism: The Maastricht Study
Objective: To ascertain the cross-sectional association between cardiovascular autonomic function and arterial stiffness across glucose metabolism status. Methods: We performed a cross-sectional analysis of participants of The Maastricht Study without prior CVD. Cardiovascular autonomic function was based on heart rate variability (HRV) indices from 24-hour electrocardiogram recordings and summarized in Z-scores for time and frequency domains. Aortic and carotid stiffness were assessed by carotid-femoral pulse wave velocity (PWV) and carotid artery distensibility (CD), respectively. We used multiple linear regression to study the associations and adjusted for demographic and lifestyle factors and a range of cardiovascular risk factors. We tested the modification of the associations by glucose metabolism status. Results: PWV and CD measures were available in 3671 and 1806 participants, respectively (median (25 th ; 75 th percentile) age: 60 years (53; 66), 51% women, 20 % type 2 diabetes by design. Participants with lower HRV had higher aortic stiffness, as reflected by 2.8% (CI: 2.1; 3.4) and 2.8% (2.1; 3.5) higher PWV per standard deviation (SD) lower composite HRV time-domain and frequency domain Z-score, respectively. Similar trends were observed for carotid stiffness, reflected by 3.2% (1.4; 5.0) and 3.1% (1.2; 5.0) lower CD per SD lower composite HRV time-domain and frequency domain Z-score, respectively. Associations were stronger among people with prediabetes and type 2 diabetes compared to normal glucose metabolism (p-value for interaction for prediabetes: <0.05; and for type 2 diabetes ranging between: <0.05 - <0.10). Conclusion: Cardiovascular autonomic dysfunction is associated with higher aortic and carotid stiffness, especially in people with dysglycemia. Thus, autonomic dysfunction may contribute to cardiovascular risk by affecting vascular stiffness. Short This study investigates the association between cardiovascular autonomic function and arterial stiffness in 3,671 participants of The Maastricht Study without prior CVD. Cardiovascular autonomic function was assessed using 24-hour heart rate variability (HRV). Aortic stiffness was measured by pulse wave velocity (PWV), and carotid stiffness by carotid artery distensibility (CD). Lower HRV was associated with 2.8–3.2% higher PWV and 3.1–3.2% lower CD per SD decrease in HRV Z-scores, with stronger associations observed in individuals with dysglycemia. These findings suggest that autonomic dysfunction may increase cardiovascular risk through effects on vascular stiffness, particularly in prediabetes and diabetes.
- 5 August 2024
- Published by SAGE Publications in Journal of Dental Research
- Vol. 103 (9) , 870-877
Periodontitis and Diabetes Complications: A Danish Population-Based Study
Conflicting evidence suggests a link between diabetes-related microvascular complications and periodontitis. Reliable estimates have been hindered by small sample sizes and residual confounding. Moreover, the combined effects of microvascular complications and dyslipidemia on periodontitis have not been explored. Therefore, this study aimed to investigate the association between individual and combined diabetic microvascular complications (i.e., neuropathy and retinopathy) and moderate/severe periodontitis in a Danish population-based study. In addition, we assessed whether dyslipidemia modified these associations. This study comprised 15,922 participants with type 2 diabetes from the Health in Central Denmark study. Multinomial logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for individual and joint microvascular diabetes complications. The models adjusted for potential confounders, including sociodemographic factors, lifestyle behaviors, and health conditions. Inverse probability of treatment weighting (IPTW) balanced measured confounders between periodontitis and nonperiodontitis participants. Sensitivity analyses tested the findings’ robustness by estimating E-values for unmeasured confounding and varying microvascular complication definitions. After IPTW, adjusted models revealed that diabetic neuropathy (OR 1.36, 95% CI 1.14 to 1.63) and retinopathy (OR 1.21, 95% CI 1.03 to 1.43) were significantly associated with moderate/severe periodontitis. Moreover, the coexistence of microvascular complications increased the odds 1.5-fold for moderate/severe periodontitis (OR 1.51, 95% CI 1.23 to 1.85). An effect modification of dyslipidemia on an additive scale was found, indicated by a positive relative excess risk due to interaction of 0.24 for neuropathy, 0.11 for retinopathy, and 0.44 for both complications. Sensitivity analysis ruled out unmeasured confounders and microvascular complication definitions as explanatory factors. Diabetic neuropathy and retinopathy, individually and combined, were associated with moderate/severe periodontitis. In addition, dyslipidemia had an additive positive effect modification on diabetic microvascular complications, elevating the odds of moderate/severe periodontitis. These findings may aid in identifying at-risk subgroups for diabetes-related microvascular complications and periodontitis, optimizing efforts to mitigate disease burden.
- 5 August 2024
- Published by SAGE Publications in Journal of Dental Research
- Vol. 103 (9) , 870-877
Periodontitis and Diabetes Complications: A Danish Population-Based Study
Conflicting evidence suggests a link between diabetes-related microvascular complications and periodontitis. Reliable estimates have been hindered by small sample sizes and residual confounding. Moreover, the combined effects of microvascular complications and dyslipidemia on periodontitis have not been explored. Therefore, this study aimed to investigate the association between individual and combined diabetic microvascular complications (i.e., neuropathy and retinopathy) and moderate/severe periodontitis in a Danish population-based study. In addition, we assessed whether dyslipidemia modified these associations. This study comprised 15,922 participants with type 2 diabetes from the Health in Central Denmark study. Multinomial logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for individual and joint microvascular diabetes complications. The models adjusted for potential confounders, including sociodemographic factors, lifestyle behaviors, and health conditions. Inverse probability of treatment weighting (IPTW) balanced measured confounders between periodontitis and nonperiodontitis participants. Sensitivity analyses tested the findings’ robustness by estimating E-values for unmeasured confounding and varying microvascular complication definitions. After IPTW, adjusted models revealed that diabetic neuropathy (OR 1.36, 95% CI 1.14 to 1.63) and retinopathy (OR 1.21, 95% CI 1.03 to 1.43) were significantly associated with moderate/severe periodontitis. Moreover, the coexistence of microvascular complications increased the odds 1.5-fold for moderate/severe periodontitis (OR 1.51, 95% CI 1.23 to 1.85). An effect modification of dyslipidemia on an additive scale was found, indicated by a positive relative excess risk due to interaction of 0.24 for neuropathy, 0.11 for retinopathy, and 0.44 for both complications. Sensitivity analysis ruled out unmeasured confounders and microvascular complication definitions as explanatory factors. Diabetic neuropathy and retinopathy, individually and combined, were associated with moderate/severe periodontitis. In addition, dyslipidemia had an additive positive effect modification on diabetic microvascular complications, elevating the odds of moderate/severe periodontitis. These findings may aid in identifying at-risk subgroups for diabetes-related microvascular complications and periodontitis, optimizing efforts to mitigate disease burden.
- 19 March 2024
- Published by American Diabetes Association in Diabetes Care
- Vol. 47 (6) , 986-994
Longitudinal Change in Serum Neurofilament Light Chain in Type 2 Diabetes and Early Diabetic Polyneuropathy: ADDITION-Denmark
OBJECTIVE: To investigate the longitudinal development of neurofilament light chain (NfL) levels in type 2 diabetes with and without diabetic polyneuropathy (+/−DPN) and to explore the predictive potential of NfL as a biomarker for DPN. RESEARCH DESIGN AND METHODS: We performed retrospective longitudinal case-control analysis of data from 178 participants of the Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care-Denmark (ADDITION-Denmark) cohort of people with screen-detected type 2 diabetes. Biobank samples acquired at the ADDITION-Denmark 5- and 10-year follow-ups were analyzed for serum NfL (s-NfL) using single-molecule array, and the results were compared with established reference material to obtain NfL z-scores. DPN was diagnosed according to Toronto criteria for confirmed DPN at the 10-year follow-up. RESULTS: s-NfL increased over time in +DPN (N = 39) and −DPN participants (N = 139) at levels above normal age-induced s-NfL increase. Longitudinal s-NfL change was greater in +DPN than in −DPN participants (17.4% [95% CI 4.3; 32.2] or 0.31 SD [95% CI 0.03; 0.60] higher s-NfL or NfL z-score increase in +DPN compared with −DPN). s-NfL at the 5-year follow-up was positively associated with nerve conduction studies at the 10-year follow-up (P = 0.02 to <0.001), but not with DPN risk. Areas under the curve (AUCs) for s-NfL were not inferior to AUCs for the Michigan Neuropathy Screening Instrument questionnaire score or vibration detection thresholds. Higher yearly s-NfL increase was associated with higher DPN risk (odds ratio 1.36 [95% CI 1.08; 1.71] per 1 ng/L/year). CONCLUSIONS: Our findings suggest that preceding s-NfL trajectories differ slightly between those with and without DPN and imply a possible biomarker value of s-NfL trajectories in DPN.
- 19 March 2024
- Published by American Diabetes Association in Diabetes Care
- Vol. 47 (6) , 986-994
Longitudinal Change in Serum Neurofilament Light Chain in Type 2 Diabetes and Early Diabetic Polyneuropathy: ADDITION-Denmark
OBJECTIVE: To investigate the longitudinal development of neurofilament light chain (NfL) levels in type 2 diabetes with and without diabetic polyneuropathy (+/−DPN) and to explore the predictive potential of NfL as a biomarker for DPN. RESEARCH DESIGN AND METHODS: We performed retrospective longitudinal case-control analysis of data from 178 participants of the Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care-Denmark (ADDITION-Denmark) cohort of people with screen-detected type 2 diabetes. Biobank samples acquired at the ADDITION-Denmark 5- and 10-year follow-ups were analyzed for serum NfL (s-NfL) using single-molecule array, and the results were compared with established reference material to obtain NfL z-scores. DPN was diagnosed according to Toronto criteria for confirmed DPN at the 10-year follow-up. RESULTS: s-NfL increased over time in +DPN (N = 39) and −DPN participants (N = 139) at levels above normal age-induced s-NfL increase. Longitudinal s-NfL change was greater in +DPN than in −DPN participants (17.4% [95% CI 4.3; 32.2] or 0.31 SD [95% CI 0.03; 0.60] higher s-NfL or NfL z-score increase in +DPN compared with −DPN). s-NfL at the 5-year follow-up was positively associated with nerve conduction studies at the 10-year follow-up (P = 0.02 to <0.001), but not with DPN risk. Areas under the curve (AUCs) for s-NfL were not inferior to AUCs for the Michigan Neuropathy Screening Instrument questionnaire score or vibration detection thresholds. Higher yearly s-NfL increase was associated with higher DPN risk (odds ratio 1.36 [95% CI 1.08; 1.71] per 1 ng/L/year). CONCLUSIONS: Our findings suggest that preceding s-NfL trajectories differ slightly between those with and without DPN and imply a possible biomarker value of s-NfL trajectories in DPN.